ISRCTN30587563已完成3 期
ational multicentre study of magnetic resonance imaging (MRI) as a method of screening for breast cancer in women at genetic risk
Medical Research Council (MRC) (UK)0 个研究点目标入组 900 人开始时间: 2010年6月18日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 900
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1. Women aged 35 - 49 years
- •2. Tested BRCA1 or BRCA2 carriers
- •3. Known mutation in first degree relative
- •4. Family history of breast and ovarian cancer (four or more relatives)
- •1. Women aged 25 - 49 years
- •2. Tested p53 carriers
- •3. Known mutation in a first degree relative
- •4. Family history consistent with Li Frameni syndrome
排除标准
- •1. Previous breast cancer (including ductal carcinoma in situ [DCIS])
- •2. Terminal illness, or life expectancy of less than 5 years
- •3. Pregnancy or breast-feeding (recruitment suspended until breast-feeding has finished)
- •4. Current chemotherapy (recruitment suspended until 6 months after treatment ceases; exclusion 2, above, still applies)
研究者
相似试验
进行中（未招募）
不适用
Open-label multi-center study of magnetic resonance imaging (MRI) with 0.1 mmol/kg BW Gadovist (1.0 M) to assess pharmacokinetics, safety and tolerability in childreEUCTR2006-004153-22-ATBayer Schering Pharma140
进行中（未招募）
不适用
Open-label multi-center study of magnetic resonance imaging (MRI) with 0.1 mmol/kg BW Gadovist (1.0 M) to assess pharmacokinetics, safety and tolerability in childreGadovist as diagnostic imaging agent is approved only for adult patients. Diseases usually representing indications for contrast-enhanced Magnetic Resonance Imaging (CE-MRI) are common also in a pediatric population. This study is a clinical routinely study in pediatric patients (male/ female) aged 2-17 years (3 age groups: 2-6, 7-11, and 12-17 years) who are scheduled to undergo Gd-enhanced MRI of brain, spine, liver and/or kidneys or Gd-enhanced MRA (single field of view).MedDRA version: 9.1Level: PTClassification code 10029815Term: Nuclear magnetic resonance imagingEUCTR2006-004153-22-SEBayer AB, Bayer Health Care, Bayer Schering Pharma140
进行中（未招募）
不适用
Open-label multi-center study of magnetic resonance imaging (MRI) with 0.1 mmol/kg BW Gadovist (1.0 M) to assess pharmacokinetics, safety and tolerability in childreGadovist as diagnostic imaging agent is approved only for adult patients. Diseases usually representing indications for contrast-enhanced Magnetic Resonance Imaging (CE-MRI) are common also in a pediatric population. This study is a clinical routinely study in pediatric patients (male/ female) aged 2-17 years (3 age groups: 2-6, 7-11, and 12-17 years) who are scheduled to undergo Gd-enhanced MRI of brain, spine, liver and/or kidneys or Gd-enhanced MRA (single field of view).MedDRA version: 9.1Level: PTClassification code 10029815Term: Nuclear magnetic resonance imagingEUCTR2006-004153-22-DEBayer Schering Pharma AG140
进行中（未招募）
不适用
Open-label multi-center study of magnetic resonance imaging (MRI) with 0.1 mmol/kg BW Gadovist (1.0 M) to assess pharmacokinetics, safety and tolerability in childreGadovist as diagnostic imaging agent is approved only for adult patients. Diseases usually representing indications for contrast-enhanced Magnetic Resonance Imaging (CE-MRI) are common also in a pediatric population. This study is a clinical routinely study in pediatric patients (male/ female) aged 2-17 years (3 age groups: 2-6, 7-11, and 12-17 years) who are scheduled to undergo Gd-enhanced MRI of brain, spine, liver and/or kidneys or Gd-enhanced MRA (single field of view).MedDRA version: 9.1Level: PTClassification code 10029815Term: Nuclear magnetic resonance imagingEUCTR2006-004153-22-DKBayer AB, Bayer Schering Pharma140
尚未招募
不适用
A study of Magnetic Resonance Imaging(MRI) evaluation in knee joint pathologies.CTRI/2018/05/013938Department of Radiodiagnosis Government Medical College and Sir T HospitalBhavnagar